NZ616691B2 - High-frequency electrical nerve block - Google Patents
High-frequency electrical nerve block Download PDFInfo
- Publication number
- NZ616691B2 NZ616691B2 NZ616691A NZ61669112A NZ616691B2 NZ 616691 B2 NZ616691 B2 NZ 616691B2 NZ 616691 A NZ616691 A NZ 616691A NZ 61669112 A NZ61669112 A NZ 61669112A NZ 616691 B2 NZ616691 B2 NZ 616691B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- nerve
- pain
- electrode
- waveform
- peak
- Prior art date
Links
- 210000005036 nerve Anatomy 0.000 title claims abstract description 75
- 210000000578 peripheral nerve Anatomy 0.000 claims abstract description 13
- 208000004296 neuralgia Diseases 0.000 claims abstract description 11
- 230000001953 sensory effect Effects 0.000 claims abstract description 5
- 230000036982 action potential Effects 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 10
- 210000003497 sciatic nerve Anatomy 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 8
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 6
- 208000018198 spasticity Diseases 0.000 claims description 5
- 210000002972 tibial nerve Anatomy 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 3
- 239000011800 void material Substances 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 description 75
- 238000000034 method Methods 0.000 description 35
- 239000004020 conductor Substances 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 239000012811 non-conductive material Substances 0.000 description 11
- 230000035807 sensation Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010020853 Hypertonic bladder Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000002266 amputation Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000007830 nerve conduction Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 208000020629 overactive bladder Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
- A61N1/0556—Cuff electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36071—Pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/3615—Intensity
- A61N1/3616—Voltage density or current density
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
- A61N1/36167—Timing, e.g. stimulation onset
- A61N1/36171—Frequency
Abstract
device for ameliorating sensory nerve pain in a patient in need thereof, the device comprising: an implanted electrode (50) and a waveform generator (10). The implanted electrode (50) contacts a trunk of a sensory peripheral nerve in the patient at a plurality of contact surfaces with the nerve trunk. The waveform generator (10) is operatively connected to the implanted electrode for generating a waveform at one of a voltage ranging from 4 Volt peak-to-peak (Vpp) to 20 Vpp, or a current ranging from 4 milli-Amp peak-to-peak (mApp) to 26 mApp. unk. The waveform generator (10) is operatively connected to the implanted electrode for generating a waveform at one of a voltage ranging from 4 Volt peak-to-peak (Vpp) to 20 Vpp, or a current ranging from 4 milli-Amp peak-to-peak (mApp) to 26 mApp.
Description
HIGH-FREQUENCY ICAL NERVE BLOCK
This application claims priority to co-pending US. application Serial No. 61/487,877
filed May 19, 2011, which is expressly incorporated by reference herein in its entirety.
In one embodiment, successful results are disclosed from a method and tus
that uses high frequency nerve block to acutely treat peripheral pain, either acute pain or
chronic pain (more than 6 months in duration), in humans by blocking nerve conduction on an
action potential. Acute treatment is defined as on demand treatment with substantially
immediate pain relief effect. In one embodiment, the method is used in peripheral nerves
having a diameter up to about 12 mm, i.e., in relatively large nerves such as the sciatic nerve.
In one embodiment, the method is used on a nerve to ameliorate a in condition by
therapy to a nerve, e.g., motor nerves resulting in spasticity, e.g., nerves providing an urge to
void in overactive bladder.
Previous therapy for pain of peripheral origin, e.g., damaged nerves in a limb,
consisted of one or a combination of the following methods.
One previous therapy was local injection of a pharmacologic anesthetic such as
lidocaine. The therapeutic effect often lasts only a short time, e.g., a few hours. Repeated
dosing is typically not feasible because of toxicity of the anesthetic and other reasons.
Another previous therapy was conventional electrical ation by surface
electrodes or surgically implanted electrodes (e.g., TENS, Peripheral Nerve and Spinal Cord
Stimulator). ical stimulation therapy is used to treat back pain and joint pain, but
es istent effects. The inconsistencies are due to the indirect nature of the
therapy; instead of blocking pain signals from the origin of the pain, this type of electrical
stimulation activates non-pain sensory nerves to generate other types of sensation (e.g.,
tingling) that mask the pain sensation. Such masking is by a complex, and often unreliable,
interaction of various parts of the nervous system.
A potential therapy involves ibly blocking peripheral nerves by ng high
frequency alternating current ly on a nerve trunk. Specifically, a current ranging from 5
kHz to 50 kHz was applied; this was denoted as high frequency, compared to a current of less
than 1 kHz applied in the conventional electrical stimulation bed above. Efficacy of the
high frequency ating current therapy in acute non-human animal experiments (frog, cat)
has been reported. US. Patent Nos. 7,389,145 and 208 describe in general this
electrical stimulation logy. No data are described.
One embodiment of the invention ses a method for reversibly blocking an action
potential in a peripheral nerve having a diameter exceeding 3 mm and up to about 12 mm,
e.g., a c nerve, a tibial nerve, etc., in a patient in need f. The method comprises
providing an electrical waveform for an interval of time sufficient to effect substantially
immediate pain relief, defined generally as within about 10 min. One embodiment uses a
waveform ranging from 5 kHz to 50 kHz. One embodiment uses a 10 kHz sinusoidal
waveform at a current ranging from 4 mApp to 26 mApp. The electrode can be retained in a
cuff encircling the desired peripheral nerve in which the action potential is to be blocked; the
cuff inner diameter may range from about 5 mm to about 12 mm. The time interval may be
about 10 minutes, but an interval may be selected by a magnitude sufficient to effect pain
relief in the patient. In one embodiment, the electrical waveform to effect pain relief ranges
from a e from 4 Vpp to 20 Vpp, or a current ranging from 4 mApp to 26 mApp. The time
of increasing magnitude can range from about 10 seconds to about 60 seconds with a steady
ramp up of voltage or current. The waveform is provided by a waveform generator that is
operatively connected to the electrode implanted in the t; such methods are known in
the art.
One embodiment is a device that reversibly blocks an action potential in a relatively
large nerve, Le, a nerve with a diameter exceeding about 3 mm and up to 12 mm. The
apparatus has a self-curling sheet of non-conductive al that includes a first layer, which
is pre-tensioned, and a second layer, which is not pre-tensioned. The two layers are
configured to form a cuff containing or holding strips of conducive al therebetween. ln
embodiments, the device has one, two, three, four or more continuous strips of a conductive
material that are ed adjacent, but not transverse, to one longitudinally ing edge
of the self-curling sheet, each of these strips of conductive material is connected to an
electrically conductive lead. In one embodiment, the device contains one strip of a conductive
material, termed a monopolar configuration. In one embodiment, the device contains at least
two continuous strips, connected by an electrically conductive lead, of a conductive material,
termed a bipolar configuration. In one embodiment, the device contains at least three
continuous strips, ted by an electrically conductive lead, of a conductive material,
termed a ar configuration. In one embodiment, the device contains at least four
continuous strips, ted by an electrically conductive lead, of a conductive material.
Multiple apertures, typically circular but not necessarily so limited in shape, are ed at
periodic intervals of the inner contacting surface along the curling length of one of the
two non-conductive sheets or layers of the self-curling sheet / cuff. This provides contact to
the nerve by exposing and providing continuous multiple tive contact points. The
exposure may be at any interval that exposes as much of the conductive material as possible
or desirable, and exceeds the contact surface area of conventional electrodes. Each of the
first or top non-conductive sheet or layer and the second or bottom non-conductive sheet or
layer still retains and contains the conductive material therebetween, i.e., ched inside
the sheets or layers, so that the conductive material is in fact retained and does not pop out or
come out while providing efficient t delivery. In one embodiment the non-conductive
material is silicon, the electrically conductive lead is stainless steel, and the conductive
material is platinum. Other materials for each of the non-conductive material, the electrically
tive lead or wire, and the tive material are known in the art. In use, the device
is operatively connected, e.g., by an external lead or wire, to a waveform generator that
provides the regulated waveform.
One embodiment is a method for treating peripheral nerve pain in a patient in need of
this treatment. The described device encircled a particular segment of a targeted
peripheral nerve, e.g., a sciatic nerve, a tibial nerve. Using a patient-implanted electrode
connected to an electrical waveform generator, an electrical waveform is applied for a time
interval, e.g., 10 min, sufficient to effect substantially immediate patient pain relief, e.g., within
min, and an extended period of pain relief up to several hours. The current in one
embodiment ranges from 4 mApp to 26 mApp, and in one embodiment ranges from 4 mApp
to 26 mApp.
In the inventive , data from a human study using high frequency ical
nerve block technology for pain management are provided. In one embodiment, the result
was that amputation pain was reduced. Application of 10 kHz alternating current generated
by a custom tor via a custom implanted nerve electrode significantly reduced pain in
the majority of patients treated by the method. The required e / current level is
reported. The duration for achieving le pain relief in specific human nerves is reported.
The required sequence and time to apply the electrical energy to minimize side effects is
ed. The anticipated accompanying sensations and their time course is reported. The
duration of pain relief after termination of the electrical t is reported. The cumulative
effect of successive applications of the current on the extent of pain reduction is reported.
The apparatus was an implantable electrode operatively connected to an external or
ted waveform generator. The electrode was a spiral cuff electrode similar to that
described in U.S. Patent No. 624, more fully described below. In use, the electrode
was implanted in a human mammal on a desired peripheral nerve trunk proximal to the pain
source (e.g., a neuroma), such that the cuff encircled the desired peripheral nerve in which
the action potential was to be blocked. The cuff inner diameter ranged from about 5 mm to
about 12 mm. The sciatic nerve is known to have a relatively large nerve trunk; the diameter
of the proximal part of the c nerve in a human adult is about 12 mm. In one
embodiment, the apparatus and method was used on the sciatic nerve to treat limb pain in
above knee amputees. In one embodiment, the apparatus and method was used on the tibial
nerve to treat limb pain in below knee amputees.
BRIEF PTION OF THE DRAWINGS
is a perspective view of an external waveform generator and interconnection
cable.
shows an in-use implanted waveform generator operably connected to a nerve
cuff electrode encircling a patient’s nerve.
FIGS. 3A, 3B are a photograph on the implanted cuff and electrode, and a
confirmatory fluoroscopy image of same, tively.
schematically shows the nerve cuff electrode and lead.
graphs one patient’s pain relief comparing use of the invention versus drug
treatment.
graphs one patient’s pain intensity and pain relief using the invention.
shows a l schematic of a ar electrode in an uncurled
configuration; shows one embodiment of with specific dimensions.
tes treatment outcomes from five patients.
In use, the al and implanted waveform generator, shown in FIGS 1 and 2
respectively, delivered high frequency alternating current in any form (sinusoidal wave,
rectangular, other shape) sufficient to block the nerve action potential. In use, the operator
selectively regulated the amount of current applied to the electrode, the duration, and any
other desired parameters (e.g., continuous versus intermittent), etc. for therapy. In one
embodiment, a sinusoidal waveform frequency of 10 kHz effectively and repeatedly reduced
pain. In one embodiment, a sinusoidal waveform frequency ranging from 20 kHz to 30 kHz
effectively reduced pain, but required about two times higher voltage and higher current for a
kHz sinusoidal waveform, and about three times higher voltage and higher current for a 30
kHz sinusoidal waveform, compared to that required for a 10 kHz sinusoidal waveform.
Using a sinusoidal waveform frequency of 10 kHz, patients reported a ion
threshold at a voltage ranging from 1 Vpp to 10 Vpp, and at a current ranging from 1 mApp to
16 mApp. The sensation threshold was the minimum stimulation at which a patient indicated
that s/he feels a sensation due to the applied t, e.g., a patient may feel a tingling
sensation.
Indication of a sensation threshold does not indicate pain relief, which is defined
broadly as any pain mitigation or ration including but not d to complete pain relief.
Using a sinusoidal waveform of 10 kHz, the patient's relief from pain was achieved at a
voltage ranging from 4 Vpp to 20 Vpp, and at a current ranging from 4 mApp to 26 mApp.
The al between the two parameters (the voltage / current required to be applied to
achieve a sensation threshold, versus the voltage / current required to be applied to achieve
pain relief) was optimally achieved by a vative steady ramping up over a range from
about 10 seconds to about 60 s. This minimized or prevented the t from
experiencing pain or other undesirable sensations at the outset of therapy.
In one ment, the electrode was implanted on the tibial nerve, as shown in FIG
3A. Proper tation was verified by fluoroscopy visualization, as shown in .
In one of five ts experiencing pain post lower-limb amputation, the extent of
baseline pain intensity and relief of this pain by a self-administered narcotic pill were
compared to the extent of each of baseline pain ity and relief of this pain using the
sed nerve block apparatus and method was self-assessed over a 21 consecutive day
period. The patient self-assessed pain intensity using a 0-10 scale where 0 is no pain and 10
is as bad as it could be. The narcotic was hydrocodone/APAP formulated as a tablet at a
dose of 10 mg / 325 mg. The patient self-administered the tablet orally as needed.
When self-administering the electrical nerve block therapy, the parameters over
which the patient did not have control were the amount of current applied, and the on of
each administration period. The parameters over which the patient did have control were the
time(s) during the 24 hour period to self-administer the therapy, and the time interval n
the administrations. In one embodiment, each treatment was for 10 minutes. In one
ment, one dministered electrical treatment for 10 minutes was immediately
followed by at least one additional self-administered electrical treatment for 10 minutes to
result in cumulative pain reduction effect. The amount of current / voltage applied during
each interval ranged from 4 mApp to 26 mApp / 4 Vpp to 20 Vpp, respectively.
Specific selected data for each of two patients are shown in FIGS. 5 and 6
respectively. A summary of the results for all of the five patients is shown in
The patients reported that they experienced pain mitigation within minutes of
ent onset. The patients reported that sensations such numbness, tingling, and pulling,
subsided within minutes after treatment onset. The ts reported that, after a 10 min
ent (application of electrical blocking t), they experienced pain reduction that was
sustained up to several hours after ion of treatment.
A ption of s embodiments of the electrode used for nerve conduction
block is as follows. They differ from the use of the apparatus disclosed in Naples U.S. Patent
No. 4,602,624. Naples' electrode is used to stimulate, i.e., excite, activate, generate, an
action potential in a nerve having a diameter of about 1 mm to about 3 mm. In Naples, four
sets of rectangular-shaped electrodes constitute the contact points that are sandwiched
between two layers of a non-conductive material such as silicon. The layers of non-
conductive material were self-curling. The conductive contact points were disposed at
uniform intervals etween at sites on the inner circumference of a first resiliently
extensible layer. The conductive contact points are connected by conductive wires or leads,
e.g., stainless steel wires. The layers have openings (windows) in the nductive
material to expose the conductive contact points to the nerve upon ive regulation, in this
case, tion to initiate an action potential. The distance between the openings (separation
distance) and curling length of the layers is proportional to the nerve diameter.
In attempting to block an action ial in nerves having a diameter ing
about 3 mm, the previously bed apparatus and method is inadequate. This is because
a simple scale-up of the aforementioned design did not permit adequate current flow that is
necessary to block conduction of an action potential in a nerve that has a relatively larger
diameter as compared to a typical nerve which has a er that does not exceed about 3
mm. For example, the sciatic nerve in an adult human has a diameter exceeding about 3
mm; it can be up to 12 mm diameter. The sciatic nerve is a frequent source of pathology and
often requires therapy. The inventive method was used on nerves having a diameter
exceeding about 3 mm for nerve conduction block.
In one embodiment the inventive method was used on nerves having a diameter
between about 1 mm and about 8 mm. In one embodiment the inventive method was used
on nerves having a diameter between about 3 mm and about 10 mm. In one embodiment the
inventive method was used on nerves having a diameter between about 8 mm and about 12
mm. In one embodiment the ive method was used on nerves having a diameter up to
about 12 mm. The inventive method blocked an action potential in a nerve, including the
sciatic nerve, and thus ameliorated and/or mitigated peripheral nerve pain. The inventive
method was not used to generate an action potential in a nerve; rather, it was used to block
conduction of an action ial. Blocking tion of an action potential in a nerve,
versus stimulating an action potential in a nerve, requires higher current, and hence lower
resistance, at the interface between the nerve and the electrode. The inventive method used
a generator that advantageously provided adequate voltage with lower power consumption.
The inventive method thus minimized thermal damage to tissue from heat that was generated
during its use, while providing improved efficiency.
In all embodiments, the electrode had a relatively larger contact surface with the
nerve than conventional electrodes, such as Naples’ electrode. As only one illustrative
example used in the inventive method, the apertures were spaced at an interval ranging from
0.5 mm up to 1.9 mm. In one embodiment, the apertures were spaced at 1.0 mm intervals,
defined as a center-to-center dimension between neighboring apertures.
As shown in an external rm tor 10 had an electrode connector
ively connected with cable 25, having connector 13, LED indicator 15, and on / off
indicator 17. As shown in use in FIGS. 2, 3, and 4, nerve cuff ode 50 had conductive
material 51 contained in self-curing sheet 53 and lead 25 to t to the waveform
generator 10. As best shown in FIGS. YA, YB, the conductive material 51 was both contained
and retained within an implantable expandable spiral cuff 52, shown in The cuff 52
ed the flexibility required for use to t and regulate nerves having a diameter
exceeding about 3 mm and up to about 12 mm, and provided a non-rigid contact surface with
the nerve in order to minimize tissue .
In one embodiment, shown in general FIG. YA and in one specific ment shown
in FIG. YB, the electrode contained continuous strips of tive material 51, specifically
platinum in FIG. YB, in a sandwich configuration, with two ng surfaces or sheets of a
non-conductive material 53, specifically silicon in FIG. YB, along the entire length of the non-
conductive material 53. The nductive material 53 was self-curling. To provide points
of contact of conductive material 51 with the nerve, around which the cuff 52 was implanted,
openings or apertures 57 were created in one surface of the non-conductive al 53 at
periodic intervals 59. The spacing of the intervals 59 is such that the conductive material 51
was contained and retained within the non-conductive material 53 during use, i.e., the non-
conductive material does not pop out or come out, and provides sufficient exposure of the
conductive material 51 for electrical contact with the nerve. In one embodiment, the openings
57 were created at 1 mm intervals. In one embodiment, the openings 57 were created at
intervals ranging between about 1 mm to about less than 2 mm. The openings 57 were
created in the non-conductive material 53; it was at these openings 57 that the nerve was
exposed to the conductive material 51 in order to block conduction of an action ial. In a
bi- or tri-polar embodiments, the distance or spacing between strips is 1 : 1 depending upon
the nerve size to be treated; larger sized nerves can accommodate larger space between the
strips. In FIG. YA, for each electrode, the strip length with tive material contacts YO is
shown for each of leads or wires A, B, and C. This electrode design achieved efficient current
delivery to effect this blockage of the action potential. This electrode design contained and
retained the conductive material 51 within the two layers of nductive material 53.
In one embodiment, the curled uration of the apparatus had a diameter of 10
mm with a 1.5 wrap, meaning that one half of the circumference contained a single
sandwiched sheet (i.e., 2 layers) of non-conductive material 53, and the other 1.5 wrap of the
circumference contained two sandwiched sheets (i.e., 4 layers) of non-conductive material 53.
Any wrap resulting in a compliant, flexible cuff that does not damage the nerve may be used.
The olar distance was about 0.75 times to 1.5 times the inner cuff diameter. The
contact surface area was relatively larger than the t surface area of conventional
electrodes, such as the electrode Naples disclosed for nerve stimulation and activation, safely
delivered the required higher amount of charge to block the nerve action ial, even in
nerves up to 12 mm in diameter.
In one embodiment, the electrode was bipolar. In another embodiment, the electrode
used three contact groups, i.e., tripolar. In this embodiment, the electrode contained three
continuous strips of conductive material, connected by electrically conductive leads (A, B, C in
FIGS. 7A, 78), that was provided between the two opposing non-conductive surfaces in the
same manner as described above for two uous strips of tive material. The
tion, i.e., distance, between the two, three, or more conductor bands is a function of
the diameter of the cuff. The ratio of separation : diameter ranged between 0.75 : 1.5.
The above-described electrode blocked numerous nerve fascicles and/or nerve
fibers. The ge was reversible; the cuff was implantable along any length of nerve at
any site, and electrical parameters (current, voltage, duration, etc.) were selected by the
operator. In one embodiment, the recipient of the implantable tus is the operator. In
one embodiment, a health care professional is the operator. Use of the electrode results in
lower resistance at the interface between the nerve and the electrode. Such multiple points of
contact, and relatively large openings, enables the electrode to block at least one portion of
the nerve trunk. In the embodiment with a tripolar uration, the ode can be used to
first block at least one portion of the nerve trunk, and then stimulate the other portion to verify
blockage.
The ive method has use in a variety of pain and non-pain applications. One
embodiment uses the method and electrode to block peripheral nerve pain. Besides use to
rate amputation pain, the uses and description of which was previously described,
other examples of ameliorating pain include, but are not limited to, ameliorating athic
pain, nociceptive pain, chronic neurogenic pain, migraine pain, post-herpetic neuralgia, pelvic
pain, chronic post-surgical pain, post-surgical pain, and neuralgia. As known in the art, pain
is defined as an unpleasant sensation caused by noxious stimulation of the sensory nerve
endings. Amputation pain is pain resulting from the surgical removal of a part of the body or a
limb or a part of a limb to treat for therapy resulting from, e.g., pathology, trauma, etc.
athic pain is pain that results from the direct inputs of nervous tissue of the peripheral
or central nervous , generally felt as burning or tingling and often occurring in an area
of y loss. Nociceptive pain is pain that s from stimulation of the neural receptors
for painful stimuli, i.e., inputs of nociceptors. Chronic neurogenic pain is pain that originates
in the nervous system and persists over time (i.e., not acute but chronic). Migraine pain result
in headaches and is related to dilation of extracranial blood vessels, the origin of which may
be defined (e.g., consumption of certain foods, external stimuli) or may be unknown. Post-
herpetic neuralgia is a form of neuralgia with intractable pain that develops at the site of a
previous eruption of herpes zoster. Pelvic pain is pain that is centered in the pelvis region i.e.
lower part of the trunk of the body. Chronic post-surgical pain is pain persisting for a long
period of time beginning after treatment of disease or trauma by lative and operative
s. Post-surgical pain is pain beginning after ent of disease or trauma by
manipulative and operative methods. Neuralgia is pain, often severe and characterized as
“stabbing”, resulting from any number of nervous system pathologies or disorders.
In other embodiments, the inventive method is used in non-pain applications where
blocking the action potential of a nerve provides the desired amelioration outcome. One
example of such a non-pain use is in ameliorating obesity. As known in the art, obesity is an
abnormal increase in the proportion of fat cells, mainly in the viscera and subcutaneous
tissues. The inventive method may be used on the vagus nerve in this embodiment. r
example of such a non-pain use in ameliorating overactive bladder, which is a colloquial term
for bladder storage function ers or ogies. The method and ode can be used
on the pelvic nerve to ameliorate the sudden urge to void that may be difficult to suppress and
may lead to incontinence. Another example of such a non-pain use is in rating
spasticity of any motor nerve; spasticity results in excessive muscle ction and can be
due to any of several nervous system disorders. The following hypothetical es
illustrate these embodiments.
A patient with advanced type 2 diabetes is experiencing neuropathic pain in his feet
as a result of loss of blood flow to his legs. Normal doses of pain-killing narcotics are either
ineffective or cause undesirable side s. After implantation of the electrode and
ent of the cuff on the right sciatic nerve trunk at the popliteal fossa, the patient self-
treats pain for 10 minutes at 10 mApp, experiencing immediate pain relief. The patient
repeats the procedure on demand, as needed.
A migraine patient experiences severe headaches onsive to tional
ent. After implantation of the electrode and placement of the cuff on the greater
occipital nerve trunk, the patient self-treats pain for 10 minutes at 10 mApp, experiencing
immediate pain relief. The patient repeats the procedure on demand, as needed.
A patient with shingles experiences postherpetic neuralgia, unresponsive to
conventional treatment. After implantation of the electrode and placement of the cuff on the
intercostal nerves, the patient self-treats pain for 10 minutes at 10 mApp, encing
immediate pain relief. The patient s the procedure on demand, as needed.
A post-operative inguinal hernia repair patient experiences chronic pain. After
implantation of the electrode and placement of the cuff on the ilioinguinal nerve, the patient
reats pain for 10 s at 10 mApp, experiencing immediate pain relief. The patient
repeats the procedure on demand, as needed.
A patient with overactive bladder syndrome undergoes a procedure for implantation
of the electrode and ent of the cuff on the pelvic nerve. The patient self-treats at 10
mApp upon an urge to urinate, experiencing urge cessation.
A patient with muscle spasticity undergoes a procedure for implantation of the
ode and placement of the cuff on a motor nerve. The patient self-treats at 10 mApp
when needed, rating spasticity of the muscle to which the nerve innervates
The embodiments shown and described are specific embodiments of inventors who
are skilled in the art and are not limiting in any way. Therefore, various changes,
modifications, or alterations to those embodiments may be made without departing from the
spirit of the invention in the scope of the following claims. The references cited are sly
incorporated by reference herein in their entirety.
Claims (13)
1. A device for ibly blocking an action potential in a nerve of a patient to effect a desired response in the patient, the device comprising: an implanted electrode contacting a trunk of a nerve in the t at a plurality of contact surfaces with the nerve trunk; and a waveform tor operatively ted to the implanted electrode, generating a waveform at one of a voltage ranging from 4 Volt peak-to-peak (Vpp) to 20 Vpp, or a current ranging from 4 milli-Amp peak-to-peak (mApp) to 26 mApp.
2. The device of claim 1 where the action potential is sensory nerve pain, and the nerve is a sensory peripheral nerve.
3. The device of claim 1 or 2 where the waveform is at least 5 kHz up to 50 kHz.
4. The device of claim 1 or 2 where the waveform is a sinusoidal waveform at 10 kHz.
5. The device of any one of claims 1 to 4 where the nerve diameter is up to 12 mm.
6. The device of any one of claims 1 to 4 where the nerve diameter exceeds 3 mm and is up to 12 mm.
7. The device of any one of claims 1 to 6 where the nerve is a sciatic nerve.
8. The device of any one of claims 1 to 6 where the nerve is a tibial nerve.
9. The device of any one of claims 1 to 8 where the ted electrode is a mono-, bi-, or tri-polar electrode and contained in a cuff.
10. The device of claim 9 wherein the cuff has an inner diameter ranging from 5 mm to 12 :wxb
11. The device of any one of claims 1 to 10 where the current or e provided increases magnitude ranging from 10 seconds to 60 s with a steady ramp up.
12. The device of claim 1 where the response is ameliorating spasticity of a muscle enervated by the nerve.
13. The device of claim 1 where the response is ameliorating an urge to void a bladder.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487877P | 2011-05-19 | 2011-05-19 | |
| US61/487,877 | 2011-05-19 | ||
| PCT/US2012/038508 WO2012159002A2 (en) | 2011-05-19 | 2012-05-18 | High-frequency electrical nerve block |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ616691A NZ616691A (en) | 2015-07-31 |
| NZ616691B2 true NZ616691B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012255073B2 (en) | High-frequency electrical nerve block | |
| AU2014405934B2 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
| US10758723B2 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
| US9295841B2 (en) | High-frequency electrical nerve block | |
| US12011597B2 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
| US10632310B2 (en) | Electronic stimulation device, method of treatment and electronic stimulation system | |
| US10086197B2 (en) | Method for reducing overactive bladder syndrome and computer-readable medium thereof | |
| AU2017251817A1 (en) | Method for reducing overactive bladder syndrome and computer-readable medium thereof | |
| NZ616691B2 (en) | High-frequency electrical nerve block | |
| NZ730945B2 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
| HK1243020A1 (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks | |
| HK1243020B (en) | Nerve cuff electrode for neuromodulation in large human nerve trunks |